The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Dermatological adverse events with taxane chemotherapy
Open accessAbstract
Taxanes (docetaxel and paclitaxel) are among the most commonly prescribed anticancer drugs approved for the treatment of metastatic or locally advanced breast, non-small cell lung, prostate, gastric, head and neck, and ovarian cancers, as well as in the adjuvant setting for operable node-positive breast cancers. Although the true incidence of dermatological adverse events (AEs) in patients receiving taxanes is not known, and has never been prospectively analysed, they clearly represent one of the major AEs associated with these agents. With an increase in the occurrence of cutaneous AEs during treatment with novel targeted and immunological therapies when used in combination with taxanes, a thorough understanding of reactions attributable to this class is imperative. Moreover, identification and management of dermatological AEs is critical for maintaining the quality of life in cancer patients and for minimizing dose modifications of their antineoplastic regimen. This analysis represents a systematic review of the dermatological conditions reported with the use of these drugs, complemented by experience at comprehensive cancer centres. The conditions reported herein include skin, hair, and nail toxicities. Lastly, we describe the dermatological data available for the new, recently FDA-and EMA- approved, solvent-free nab-paclitaxel.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Gradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309
Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer
Sparano, J. A., Wang, M., Martino, S., Jones, V., Perez, E. A., Saphner, T., Wolff, A. C., Sledge, G. W., Wood, W. C., & Davidson, N. E. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707056 · Cited by 997
Socinski, M. A., Bondarenko, I., Karaseva, N. A., Makhson, A. M., Vynnychenko, I., Okamoto, I., Hon, J. K., Hirsh, V., Bhar, P., Zhang, H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5848 · Cited by 756
Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer
Jones, S. E., Erban, J., Overmoyer, B., Budd, G. T., Hutchins, L., Lower, E., Laufman, L., Sundaram, S., Urba, W. J., Pritchard, K. I., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.027 · Cited by 547
Cortes, J. E., & Pazdur, R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.10.2643 · Cited by 421
Adjuvant Dose-Dense Chemotherapy in Breast Cancer: Standard of Care in High-Risk Patients
Möbus, V. (2016) · Breast Care · doi:10.1159/000444004 · Cited by 354
Gradishar, W. J., Krasnojon, D., Cheporov, S., Makhson, A. N., Manikhas, G. M., Clawson, A., & Bhar, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5397 · Cited by 341
Radiation Recall with Anticancer Agents
Burris, H. A., & Hurtig, J. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0090 · Cited by 328
Hand-Foot Syndrome After Dose-Dense Adjuvant Chemotherapy for Breast Cancer: A Case Series
Bardia, A., Loprinzi, C. L., & Goetz, M. P. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1143 · Cited by 312
Pathobiology of chemotherapy-induced hair loss
Paus, R., Haslam, I. S., Sharov, A. A., & Botchkarev, V. A. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70553-3 · Cited by 304
Nagore, E., Insa, A., & Sanmart??n, O. (2000) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200001040-00004 · Cited by 298
Mucocutaneous reactions to chemotherapy
Susser, W. S., Whitaker-Worth, D. L., & Grant-Kels, J. M. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70488-3 · Cited by 294
The taxoids: paclitaxel and docetaxel
Gelmon, K. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90754-4 · Cited by 243
Chemotherapeutic agents and the skin: An update
Heidary, N., Naik, H., & Burgin, S. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.01.001 · Cited by 243
Araujo, J. C., Trudel, G. C., Saad, F., Armstrong, A. J., Yu, E. Y., Bellmunt, J., Wilding, G., McCaffrey, J., Serrano, S. V., Matveev, V. B., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70479-0 · Cited by 231
Miller, K. K., Gorcey, L., & McLellan, B. N. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.019 · Cited by 228
Lowe, G., Henderson, C. L., Grau, R. H., Hansen, C. B., & Sontheimer, R. D. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2010.10110.x · Cited by 208
Scotté, F., Tourani, J.-M., Banu, E., Peyromaure, M., Levy, E., Marsan, S., Magherini, E., Fabre-Guillevin, E., Andrieu, J.-M., & Oudard, S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.15.651 · Cited by 196
Ellis, P., Barrett-Lee, P., Johnson, L., Cameron, D., Wardley, A., O'Reilly, S., Verrill, M., Smith, I., Yarnold, J., Coleman, R., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60740-6 · Cited by 189
Semb, K. A., Aamdal, S., & Oian, P. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3426 · Cited by 176
Nonpharmacologic Strategies for Managing Common Chemotherapy Adverse Effects: A Systematic Review
Lotfi-Jam, K., Carey, M., Jefford, M., Schofield, P., Charleson, C., & Aranda, S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9053 · Cited by 169
Taxane-induced nail changes: incidence, clinical presentationand outcome
Minisini, A. M., Tosti, A., Sobrero, A. F., Mansutti, M., Piraccini, B. M., Sacco, C., & Puglisi, F. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg050 · Cited by 169
Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents
Lee, C., Gianos, M., & Klaustermeyer, W. B. (2009) · Annals of Allergy, Asthma & Immunology · doi:10.1016/s1081-1206(10)60078-6 · Cited by 161
Markman, M. M. (2003) · Supportive Care in Cancer · doi:10.1007/s00520-002-0405-9 · Cited by 153
Drug-Induced Lupus Erythematosus: Incidence, Management and Prevention
Chang, C. C.-C., & Gershwin, M. E. (2011) · Drug Safety · doi:10.2165/11588500-000000000-00000 · Cited by 142
Ko, Y., Canil, C., Mukherjee, S. D., Winquist, E., Elser, C., Eisen, A. F., Reaume, M. N., Zhang, L., & Sridhar, S. S. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70162-1 · Cited by 138
van den Hurk, C. J., Peerbooms, M., van de Poll-Franse, L. V., Nortier, J. W. R., Coebergh, J. W. W., & Breed, W. P. M. (2012) · Acta Oncologica · doi:10.3109/0284186x.2012.658966 · Cited by 135
Komen, M. M. C., Smorenburg, C. H., van den Hurk, C. J. G., & Nortier, J. W. R. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0332 · Cited by 111
Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization
Castells, M., Sancho‐Serra, M. D. C., & Simarro, M. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1273-x · Cited by 107
Chemotherapy and skin reactions
Fabbrocini, G., Cameli, N., Romano, M. C., Mariano, M., Panariello, L., Bianca, D., & Monfrecola, G. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-50 · Cited by 100
Nab-paclitaxel for the treatment of breast cancer: efficacy, safety, and approval
Yamamoto, Y., Kawano, I., & Iwase (2011) · OncoTargets and Therapy · doi:10.2147/ott.s13836 · Cited by 99
Speck, R. M., DeMichele, A. M., Farrar, J. T., Hennessy, S., Mao, J. J. J., Stineman, M. G., & Barg, F. K. (2012) · Supportive Care in Cancer · doi:10.1007/s00520-012-1551-3 · Cited by 97
Hot Flashes: A Review of Pathophysiology and Treatment Modalities
Morrow, P. K. H., Mattair, D. N., & Hortobágyi, G. N. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0174 · Cited by 95
Onycholysis as a complication of systemic chemotherapy
Hussain, S., Anderson, D. N., Salvatti, M. E., Adamson, B., McManus, M., & Braverman, A. S. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000515)88:10<2367::aid-cncr22>3.0.co;2-# · Cited by 91
Kluger, N., Jacot, W., Frouin, É., Rigau, V., Poujol, S., Dereure, O., Guillot, B., Romieu, G., & Bessis, D. (2012) · Annals of Oncology · doi:10.1093/annonc/mds095 · Cited by 89
Dermatologic Toxicity of Chemotherapeutic Agents
Payne, A. S., James, W. D., & Weiss, R. B. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.11.004 · Cited by 83
Cutaneous Side Effects of Cancer Chemotherapy
Hood, A. F. (1986) · Medical Clinics of North America · doi:10.1016/s0025-7125(16)30976-2 · Cited by 82
Permanent chemotherapy-induced alopecia: Case report and review of the literature
Tallon, B., Blanchard, E. M., & Goldberg, L. J. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.06.063 · Cited by 80
Macedo, L. T., Lima, J. P. N., dos Santos, L. V., & Sasse, A. D. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2129-z · Cited by 78
Scleroderma-like cutaneous lesions induced by paclitaxel: A case study
Kupfer, I., Balguérie, X., Courville, P., Chinet-Charrot, P., & Joly, P. (2003) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2003.30 · Cited by 77
Cutaneous Reactions to Chemotherapy and their Management
Wyatt, A. J., Leonard, G. D., & Sachs, D. L. (2006) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200607010-00005 · Cited by 77
Battafarano, D. F., Zimmerman, G. C., Older, S. A., Keeling, J. H., & Burn's, H. A. (1995) · Cancer · Cited by 76
Prevezas, C., Matard, B., Pinquier, L., & Reygagne, P. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09043.x · Cited by 75
Alopecia With Endocrine Therapies in Patients With Cancer
Saggar, V. R., Wu, S., Dickler, M. N., & Lacouture, M. E. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0193 · Cited by 75
Self-citationDocetaxel (taxotere) induced subacute cutaneous lupus erythematosus: report of 4 cases.
Chen, M. J., CROWSON, A. N., Woofter, M. J. A., Luca, M. B., & MAGRO, C. M. J. (2004) · PubMed · Cited by 74
Scalp cooling to prevent chemotherapy-induced hair loss: practical and clinical considerations
Mols, F., van den Hurk, C. J., Vingerhoets, A. J. J. M., & Breed, W. P. M. (2008) · Supportive Care in Cancer · doi:10.1007/s00520-008-0475-4 · Cited by 74
Life-threatening dermatologic adverse events in oncology
Rosen, A. C., Balagula, Y., Raisch, D. W., et al. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000032 · Cited by 71
Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study
Ehrlich, A., Booher, S. L., Becerra, Y., et al. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2003.09.018 · Cited by 68
Chemotherapy-induced hair loss.
Trüeb, R. M. (2010) · PubMed · Cited by 68
The taxoids: same roots, different drugs.
Hoff, D. D. V. (1997) · PubMed · Cited by 66
Itoh, M., Yanaba, K., Kobayashi, T., & Nakagawa, H. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07597.x · Cited by 65
Cutaneous Reactions to Chemotherapy: Commonly Seen, Less Described, Little Understood
Sanborn, R. E., & Sauer, D. (2007) · Dermatologic Clinics · doi:10.1016/j.det.2007.08.006 · Cited by 56
Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia
van den Hurk, C. J. G., Breed, W. P. M., & Nortier, J. W. R. (2012) · Supportive Care in Cancer · doi:10.1007/s00520-012-1465-0 · Cited by 55
Nail changes due to docetaxel—a neglected side effect and nuisance for the patient
Winther, D., Saunte, D. M. L., Knap, M. M., Haahr, V., & Jensen, A. B. (2007) · Supportive Care in Cancer · doi:10.1007/s00520-007-0232-0 · Cited by 54
Syrigou, E. I., Dannos, I., Kotteas, E. A., Makrilia, N., Tourkantonis, I., Dilana, K. D., Gkiozos, I., Saif, M. W., & Syrigos, K. N. (2011) · International Archives of Allergy and Immunology · doi:10.1159/000324454 · Cited by 53
Nail changes secondary to docetaxel
Wasner, G., Hilpert, F., Baron, R., & Pfisterer, J. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04210-0 · Cited by 51
Ohsumi, S., Shimozuma, K., Ohashi, Y., Takeuchi, A., Suemasu, K., Kuranami, M., Ohno, S., & Watanabe, T. (2012) · Oncology · doi:10.1159/000336480 · Cited by 44
A review of clinical experience with paclitaxel extravasations
Stanford, B. L., & Hardwicke, F. L. (2003) · Supportive Care in Cancer · doi:10.1007/s00520-003-0441-0 · Cited by 38
Caiado, J., & Picard, M. (2014) · Current Allergy and Asthma Reports · doi:10.1007/s11882-014-0451-7 · Cited by 38
Safety and efficacy evaluation of albumin-bound paclitaxel
Cecco, S., Aliberti, M., Baldo, P., Giacomin, E., & Leone, R. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.893293 · Cited by 37
Photo Recall Phenomenon: An Adverse Reaction to Taxanes
Ee, H. L., & Yosipovitch, G. (2003) · Dermatology · doi:10.1159/000071795 · Cited by 35
Cohen, P. R. (2009) · PubMed · Cited by 32
Syrigos, K. N., Strimbakos, G., Tourkantonis, I., Makrilia, N., Alamara, C. V., Gkiozos, I., & Syrigou, E. I. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.12.606 · Cited by 30
Chemotherapy-Related Reticulate Hyperpigmentation: A Case Series and Review of the Literature
Regnault, M. M., Gadaud, N., Boulinguez, S., Tournier, É., Lamant, L., Gladieff, L., Roche, H. H., Guenounou, S., Récher, C., & Sibaud, V. (2015) · Dermatology · doi:10.1159/000439047 · Cited by 29
Self-citationCutaneous porphyrias part II: treatment strategies
Tintle, S. J., Alikhan, A., Horner, M. E., Hand, J. L., & Davis, D. M. R. (2013) · International Journal of Dermatology · doi:10.1111/ijd.12016 · Cited by 26
Generalized pustular dermatosis following paclitaxel therapy
Weinberg, J. M., Egan, C. L., Tangoren, I. A., Li, L., Laughinghouse, K. A., & Guzzo, C. A. (1997) · International Journal of Dermatology · doi:10.1111/j.1365-4362.1997.tb01164.x · Cited by 26
Successful treatment with nab-paclitaxel after hypersensitivity reaction to paclitaxel and docetaxel
de Leon, M. C. B., Bolla, S., Greene, B., et al. (2013) · Gynecologic Oncology Case Reports · doi:10.1016/j.gynor.2013.05.003 · Cited by 24
Konishi, Y., Sato, H., Sato, N., Fujimoto, T., Fukuda, J., & Tanaka, T. (2010) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2010.01171.x · Cited by 19
Tang, L., Wang, B. Y., Sun, S., Zhang, J., Jia, Z., Lu, Y., Di, G.-H., Shao, Z. M., & Hu, X. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-232 · Cited by 15
Beutler, B. D., & Cohen, P. R. (2015) · Dermatology Practical & Conceptual · doi:10.5826/dpc.0502a24 · Cited by 13
Cited by
Huang, S., Yang, J., Shen, N., Xu, Q., & Zhao, Q. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.01.006 · Cited by 317
Paclitaxel: Application in Modern Oncology and Nanomedicine‐Based Cancer Therapy
Sharifi-Rad, J., Quispe, C., Patra, J. K., Singh, Y. D., Panda, M. K., Das, G., Adetunji, C. O., Michael, O. S., Sytar, O., Polito, L., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/3687700 · Cited by 298
Treatment Outcomes of Immune-Related Cutaneous Adverse Events
Phillips, G. S., Wu, J., Hellmann, M. D., Postow, M. A., Rizvi, N. A., Freites-Martinez, A., Chan, D., Dusza, S., Motzer, R. J., Rosenberg, J. E., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02141 · Cited by 241
Self-citationPhotoprotection: Current developments and controversies
Pellacani, G., Lim, H. W., Stockfleth, E., Sibaud, V., Brugués, A. O., & Saint Aroman, M. (2024) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.19677 · Cited by 56
Self-citationChemotherapy use and survival among young and middle-aged patients with gastric cancer
Jiang, Y., Xie, J., Huang, W., Chen, H., Xi, S., Li, T., Chen, C., Sun, Z., Hu, Y., Liu, W., et al. (2020) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000253 · Cited by 18
Metadata
- Authors
- Sibaud, V., Lebœuf, N. R., Roche, H., Belum, V. R., Gladieff, L., Deslandres, M., Montastruc, M., Eche, A., Vigarios, E., Dalenc, F., & Lacouture, M. E.
- Venue
- European Journal of Dermatology
- Publisher
- JLE
- Published
- 2016-09
- Volume
- 26
- Issue
- 5
- Pages
- 427-443
- ISSN
- 1167-1122 (ISSN-L)
- 1952-4013
- OpenAlex
- W2507809600
- Cited by
- 257
- References
- 73
- FWCI
- 16.05
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.